top of page

CHAI TLD Clinical Action Memo

  • hivtoolkit
  • Jul 24, 2018
  • 1 min read

This memo lays out information for programs considering introducing improved first-line products and implementation guidance for transitioning to dolutegravir (DTG) as the preferred first-line regimen, in line with WHO treatment guidelines.



Comments


  • LinkedIn
  • Facebook
  • Twitter
  • Instagram
  • YouTube

383 Dorchester Avenue, Suite 400

Boston, MA 02127

The goal of the HIV New Product Introduction Toolkit is to stimulate conversations between government, partners, and communities on new product introduction. Please feel free to share any thoughts, questions, or additional resources for consideration by contacting us via email at HIVToolkit@clintonhealthaccess.org.

 

© 2022  Clinton Health Access Initiative - Global HIV Access Program

bottom of page